Clinical trials: Anticoagulation
Mechanical Prosthetic Heart Valve Implantation, Patient Self Monitoring of Oral Anticoagulent Therapy
Benefit of Self-monitoring of Anticoagulation Instrument
To evaluate the benefit economic and medical of self-monitoring of coagulation compared with conventional follow-up of anticoagulation in a population recently fitted with mechanical heart valves.
- Trial name
- 4A (NCT00506870)
- Testing
- INRatio / Coaguchek XS
- Where
- France
- Volunteers
- 919 people
- Sponsor
- University Hospital, Bordeaux
Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute
Optimal Time for Reperfusion in Acute Pulmonary Embolism
Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality worldwide. Current guidelines recommend early reperfusion for high-risk and intermediate-high-risk PE, yet systemic thrombolysis and percutaneous…
- Trial name
- OPTIRAPE (NCT07436702)
- Where
- 7 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Azienda ULSS 8 Berica
Atrial Fibrillation
A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation
The purpose of this study is to evaluate the impact of a hospital quality improvement (QI) program on the use of guideline-recommended oral anticoagulants (OAC) in hospitalized patients with atrial fibrillation (AF) at risk for…
- Trial name
- QUANTUM AF (NCT03382613)
- Where
- 62 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Janssen Scientific Affairs, LLC
Anticoagulation With NOAC
Specific PoC Testing of Coagulation in Patients Treated With DOAC 1
The investigators study aims to test the correlation between the Cascade Abrazo point-of-care testing (POCT) device (Helena Laboratories, USA) and plasma levels of apixaban, dabigatran, edoxaban and rivaroxaban, and to determine…
- Trial name
- SPOCT-DOAC 1 (NCT02825394)
- Testing
- anti-Xa activity point-of-care testing (aXa-POCT), ecarin clotting time point-of-care testing (ECT-POCT)
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- University Hospital Tuebingen
Atrial Fibrillation, Atrial Flutter
Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in the desired therapeutic range.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction
- Trial name
- EmbraceAC (NCT00691470)
- Testing
- ATI-5923, Coumadin (warfarin)
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- ARYx Therapeutics
Atrial Fibrillation (AF)
Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)
The purpose of the PAUSE-Virtual Study is to show that by changing pre-surgery visits with patients taking a blood thinner (direct oral anticoagulant (apixaban, dabigatran, edoxaban, rivaroxaban or warfarin) when the participant…
- Trial name
- PAUSEVirtual (NCT06844227)
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 1,780 people
- Sponsor
- McMaster University
Infections, Heart Failure
Rural Hospital-Level Care at Home for Acutely Ill Adults
This study examines the implications of providing hospital-level care in rural homes.
- Conditions
- Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT05256303
- Testing
- Home Hospital care, Traditional Hospital care
- Where
- 3 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Embolism
Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux
To assess the safety and efficacy of outpatient treatment using fondaparinux and oral Vit K antagonist, warfarin (Coumadin) in patients with stable acute pulmonary embolus (APE)when initial therapy is administered in the…
- Trial name
- NCT00378027
- Testing
- Fondaparinux
- Where
- United States
- Sponsor
- The Cleveland Clinic
Bariatric Surgery, Anti-Xa Activity
The OAT Trail: The Obesity Anti-Coagulation Thromboprophylaxis Trial.
Blood clots in the legs or lungs (called venous thromboembolism or VTE) are one of the most serious complications after weight loss surgery.
- Conditions
- Bariatric Surgery, Anti-Xa Activity, VTE (Venous Thromboembolism), Obesity & Overweight
- Trial name
- The OAT-RCT (NCT07559643)
- Testing
- Anti-Xa Activity Monitoring, Tinzaparin (Leo), enoxaparin
- Where
- Ireland
- Volunteers
- 180 people
- Sponsor
- University College Dublin
Acute Kidney Injury, Renal Failure
Analysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation
The goal of this observational study is to assess the performance of the multiFlux hemofilterwith regional or systemic anticoagulation during CKRT treatments.
- Trial name
- RCA-Flux (NCT07679568)
- Testing
- multiFlux 160 hemofilter with regional heparin anticoagulation, multiFlux 160 hemofilter with RCA with regional citrate anticoagulation, multiFlux 130 hemofilter with regional heparin anticoagulation
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Deep Vein Thrombosis
Ultrasound Findings to Adjust the Duration of Anticoagulation
Prospective controlled randomized clinical trial. Consecutive patients with acute proximal deep vein thrombosis (DVT) of the lower extremities, with or without contemporary manifestations of pulmonary embolism, are randomized to…
- Trial name
- AESOPUS (NCT00380120)
- Testing
- sodium warfarin
- Where
- Italy
- Volunteers
- 538 people
- Sponsor
- University of Padova
Atrial Fibrillation (AF)
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF).
- Trial name
- DESTINATION (NCT06615596)
- Testing
- discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
- Where
- 12 sites in United States, China
- Volunteers
- 3,160 people
- Sponsor
- China National Center for Cardiovascular Diseases